HomeCompareKMNCF vs ABBV

KMNCF vs ABBV: Dividend Comparison 2026

KMNCF yields 3.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.0K in total portfolio value
10 years
KMNCF
KMNCF
● Live price
3.66%
Share price
$0.42
Annual div
$0.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$462.41
Full KMNCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KMNCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKMNCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KMNCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KMNCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMNCF
Annual income on $10K today (after 15% tax)
$310.74/yr
After 10yr DRIP, annual income (after tax)
$393.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,662.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMNCF + ABBV for your $10,000?

KMNCF: 50%ABBV: 50%
100% ABBV50/50100% KMNCF
Portfolio after 10yr
$63.8K
Annual income
$12,617.09/yr
Blended yield
19.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KMNCF
No analyst data
Altman Z
2.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMNCF buys
0
ABBV buys
0
No recent congressional trades found for KMNCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKMNCFABBV
Forward yield3.66%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$25.3K$102.3K
Annual income after 10y$462.41$24,771.77
Total dividends collected$4.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KMNCF vs ABBV ($10,000, DRIP)

YearKMNCF PortfolioKMNCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,066$365.57$11,550$430.00$484.00ABBV
2$12,218$378.06$13,472$627.96$1.3KABBV
3$13,464$390.13$15,906$926.08$2.4KABBV
4$14,808$401.78$19,071$1,382.55$4.3KABBV
5$16,257$412.98$23,302$2,095.81$7.0KABBV
6$17,819$423.74$29,150$3,237.93$11.3KABBV
7$19,501$434.07$37,536$5,121.41$18.0KABBV
8$21,310$443.95$50,079$8,338.38$28.8KABBV
9$23,255$453.39$69,753$14,065.80$46.5KABBV
10$25,345$462.41$102,337$24,771.77$77.0KABBV

KMNCF vs ABBV: Complete Analysis 2026

KMNCFStock

Kingsmen Creatives Ltd., an investment holding company, engages in exhibitions and thematic, retail and corporate interiors, research and design, and alternative marketing businesses. The company's Exhibitions and Thematic segment produces exhibition displays for trade shows and promotional events; interiors and displays for museums and visitor centers; and thematic and scenic displays for theme parks, as well as develops and operates intellectual property for experimental and themed attractions. Its Retail and Corporate Interiors segment provides interior fitting-out services to retail and commercial properties. The company's Research and Design segment offers design works for upmarket specialty stores, departmental stores, eateries, museums, visitors' centers, corporate offices, showrooms, trade shows, events, promotional functions, and festivals. Its Alternative Marketing segment provides event management, branding consultancy, and custom publishing services. In addition, the company provides design consultancy and planning management, exhibition organizers, consultancy event management, advertising, marketing communications, electrical engineering, and graphic design and production services, as well as design and construction facilities to exhibitors. Further, it designs and produces architectural interiors, decorations, and museums; operates as an advertising contractor and agent; provides corporate marketing and other related services; and manufactures, trades, and wholesales interior and exhibition furniture, fixtures, and displays. The company operates in South Asia, North Asia, the Middle East, the United States, Canada, Europe, and internationally. Kingsmen Creatives Ltd. was founded in 1976 and is headquartered in Singapore.

Full KMNCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KMNCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMNCF vs SCHDKMNCF vs JEPIKMNCF vs OKMNCF vs KOKMNCF vs MAINKMNCF vs JNJKMNCF vs MRKKMNCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.